key: cord-0797936-jh61ex5i authors: Grahl, Matheus V.C.; Alcará, Allan M.; Perin, Ana Paula A.; Moro, Carlo F.; Pinto, Éderson S.M.; Feltes, Bruno C.; Ghilardi, Isadora M.; Rodrigues, Felipe V.F.; Dorn, Marcio; da Costa, Jaderson C.; Norberto de Souza, Osmar; Ligabue-Braun, Rodrigo title: Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2 date: 2021-02-19 journal: Inform Med Unlocked DOI: 10.1016/j.imu.2021.100539 sha: 0816d58633d30b45bf7d74b1172bd315cdf52e94 doc_id: 797936 cord_uid: jh61ex5i In 2020 SARS-CoV-2 reached pandemic status, reaching Brazil in mid-February. As of now, no specific drugs for treating the disease are available. In this work, the possibility of interaction between SARS-CoV-2 viral proteins (open and closed spike protein, isolate spike protein RBD, NSP 10, NSP 16, main protease, and RdRp polymerase) and multiple molecules is addressed through the repositioning of drugs available for the treatment of other diseases that are approved by the FDA and covered by SUS, the Brazilian Public Health System. Three different docking software were used, followed by a unification of the results by independent evaluation. Afterwards, the chemical interactions of the compounds with the targets were inspected via molecular dynamics and analyzed. The results point to a potential effectiveness of Penciclovir, Ribavirin, and Zanamivir, from a set of 48 potential candidates. They may also be multi-target drugs, showing high affinity with more than one viral protein. Further in vitro and in vivo validation is required to assess the suitability of repositioning the proposed drugs for COVID-19. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic was declared 54 by the WHO in 2020. It has spread since late 2019 from the Chinese province of Hubei to the 55 rest of the world at an increasing and alarming rate, causing respiratory complications and a large 56 death toll [1, 2] . 57 Therapies against SARS-CoV-2 target the viral structure and the inflammatory storm that is 58 secondary to viral infection [3] . Surface proteins in SARS-CoV-2, called S or Spike proteins, 59 bind to target cells by the angiotensin-converting enzyme 2 (ACE2), which acts as a viral in cytokines (such as interleukins 2, 6 and 7), granulocyte colony stimulating factor, gamma 71 interferon inducing protein, monocyte chemotactic protein, inflammatory protein from coding for twenty different proteins (of which four are structural), the main therapeutic targets in 75 the SARS-CoV-2 genome are the S protein, the Main protease and the RdRp polymerase [5] . 76 The repositioning (or repurposing) of drugs guided by molecular docking is a structure-based 77 computational strategy based on the complementarity of the target binding site (receptor) and the 78 ligand (drug) [9] , the latter of which has already been approved by regulatory agencies. This 79 strategy reduces costs, considering that these drugs have already been characterized and 80 approved during clinical development [10] . In addition, the risks of candidate drugs for 81 repositioning are drastically reduced, as they already have well-established pharmacokinetic, 82 pharmacodynamic, and toxicology profiles [11] . Thus, the repositioning of drugs guided by 83 molecular docking can offer a better risk-benefit trade-off than other methods [11] . 84 Given the urgency of the SARS-CoV-2 outbreak, due to its high rate of virulence and potential 85 to collapse healthcare systems, it is extremely important to privilege the screening of existing For screening the SARS-CoV-2 viral proteins, the RCSB Protein Databank was used [14] . To increase the degree of reliability of the results, three molecular docking software were used: Table 2 ). The chemical compounds were docked with targets similar to their original ones. Only prop-2-en-1-one (nFCCl3), and Ritonavir as the best candidates. The absence of agreement among the candidates demonstrates differences in the docking 207 algorithms. To circumvent the biases of each algorithm, the Platinum server was used to rank all 208 results. Following the unification of the results using the match1 data that was generated by Table 1 . However, binding site 237 availability and steric hindrances were also taken into consideration. After defining these candidates, their interactions with other viral proteins were also evaluated. 257 We observed that Penciclovir and Ribavirin also exhibited potential for interaction with the other the target protein) were measured to assess binding stability in physiological, time-dependent conditions. 287 Full results are shown in Suppl. Figure 4 . 288 289 In this work, from the universe of generally available drugs, we were able to select 48 The COVID-19 epidemic. Tropical medicine & international 393 health Resposta imediata da Vigilância em Saúde à epidemia da COVID-395 19 COVID-19: 397 consider cytokine storm syndromes and immunosuppression Coronavirus genomics and bioinformatics analysis Structures of two coronavirus main 405 proteases: implications for substrate binding and antiviral drug design Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus 411 (COVID-19)-Induced Pneumonia Drug repurposing: 413 progress, challenges and recommendations Next-generation drug 416 repurposing using human genetics and network biology. Current opinion in pharmacology Drug repositioning: identifying and developing new uses for 419 existing drugs Therapeutic options for the 2019 novel coronavirus Drug Repurposing for COVID-2019 Data Bank PubChem 2019 update: improved access to chemical data Avogadro: 430 an advanced semantic chemical editor, visualization, and analysis platform Molecular complexes at a glance: automated generation of 433 two-dimensional complex diagrams Highly Flexible Ligand Docking: 435 Benchmarking of the DockThor Program on the LEADS-PEP Protein-Peptide Data Set AutoDock Vina: improving the speed and accuracy of docking with a 438 new scoring function, efficient optimization, and multithreading Efficient Unbound Docking of Rigid 441 Molecules2002 Consensus Docking in Drug Discovery Consensus docking: improving the reliability of docking in 445 a virtual screening context Evidence-based docking of the 447 urease activation complex Stabilized coronavirus spikes are resistant to 450 conformational changes induced by receptor recognition or proteolysis Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential 454 drugs by computational methods SARS-COV-2 non-structural protein 16: a virtual drug repurposing study Epub ahead of print Compilation of Potential Protein Targets for SARS-CoV-2: Preparation 459 of Homology Model and Active Site Determination for Future Rational Antiviral Design ChemRxiv 2020 Docking and scoring in virtual screening for 462 drug discovery: methods and applications Rumeur 466 E; French Network of Clinical Reference Centres for Neuromuscular Diseases 467 (CORNEMUS) Multidrug binding properties of the AcrB efflux pump 470 characterized by molecular dynamics simulations RND efflux pumps: structural information 473 translated into function and inhibition mechanisms PLIP: fully automated 476 protein-ligand interaction profiler Comparison of simple potential functions for simulating liquid water 1.14* CM1A-LBCC: localized bond-charge corrected CM1A charges for 480 condensed-phase simulations LigParGen web server: an automatic OPLS-AA parameter generator for 483 organic ligands High performance molecular simulations through multi-485 level parallelism from laptops to supercomputers GROMACS 2020.2 Manual Potential energy functions for atomic-level simulations of 489 water and organic and biomolecular systems Force field parametrization by weak 492 coupling. Re-engineering SPC water LINCS: a linear constraint solver for molecular simulations Particle mesh Ewald: An N⋅ log (N) method for Ewald 496 sums in large systems Constant pressure molecular dynamics for molecular systems Polymorphic transitions in single crystals: A new molecular 500 dynamics method Canonical sampling through velocity rescaling. The 502 RNA polymerase from COVID-19 virus Targeting SARS-CoV-2 Spike Protein of COVID-19 with 507 Naturally Occurring Phytochemicals: An in Silco Study for Drug COVID-19 spike-host cell receptor 509 GRP78 binding site prediction Mechanisms of coronavirus cell entry 511 mediated by the viral spike protein Proteinase and Spike Protein: From Mechanistic Studies to 514 Clinical Trials for COVID-19 Zika viral polymerase inhibition using anti-HCV drugs both in market and 516 under clinical trials Molecular dynamics and docking reveal the potency of novel GTP 518 derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life sciences SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico 521 perspective The mechanism of action of T7 DNA polymerase. Current 523 opinion in structural biology Characterization and Compatibility Studies of Penciclovir, Lysine Hydrochloride, and 526 Pharmaceutical Excipients. Materials (Basel) The Mode of Action of Penciclovir Antiherpesvirus activity of 9-(4-hydroxy-3-530 hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrobial agents and 531 chemotherapy Famciclovir, a new oral antiherpes drug: results of the first controlled clinical 533 study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster 534 in immunocompetent patients Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine 537 (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrobial agents and 538 chemotherapy Skin irritation and the inhibition effect 541 on HSV-1 in vivo of penciclovir-loaded microemulsion Broad-544 spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-545 carboxamide